| Literature DB >> 23667611 |
David Patrick Kateete1, Usuf Kabugo, Hannington Baluku, Luke Nyakarahuka, Samuel Kyobe, Moses Okee, Christine Florence Najjuka, Moses Lutaakome Joloba.
Abstract
BACKGROUND: Identification of pathogens associated with bovine mastitis is helpful in treatment and management decisions. However, such data from sub-Saharan Africa is scarce. Here we describe the distribution and antimicrobial susceptibility patterns of bacteria from cows with clinical mastitis in Kampala, Uganda. Due to high concern of zoonotic infections, isolates from milkmen are also described. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2013 PMID: 23667611 PMCID: PMC3646745 DOI: 10.1371/journal.pone.0063413
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Antimicrobial resistance among staphylococci from cows (panel A) and milkmen (panel B).
Details in Tables S1 and S2.
Antimicrobial resistance patterns among Enterococci.
| Isolates from cows (n = 16) | Comment | |
| Species/isolate | Antimicrobial resistance pattern | |
|
| ERY | |
|
| DAP-ERY | DRE |
|
| ||
|
| ||
|
| ERY | |
|
| ERY-CIP-TET | |
|
| ERY-TET | |
|
| TEI-VAN | VRE |
|
| ERY-TET | |
|
| ||
|
| TET | |
|
| ERY | |
|
| TEI-VAN | VRE |
|
| TEI-VAN | VRE |
|
| TET | |
|
| ERY-TET | |
| Isolates from humans (n = 8) | ||
|
| ERY-TET | |
|
| ERY-CIP-TET | |
|
| TET | |
|
| ||
|
| ERY | |
|
| ||
|
| ERY | |
|
| TET | |
DAP, Daptomycin; TEI, Teicoplanin; VAN; Vancomycin; ERY, Erythromycin; CIP, Ciprofloxacin; TET, tetracycline.
In boldface type are isolates that were found to be resistant to daptomycin and vancomycin, respectively (i.e., DRE, daptomycin resistant enterococcus, and VRE, vancomycin resistant enterococcus).
Antimicrobial resistance patterns among coliforms (n = 24).
| Species | Antimicrobial resistance pattern | Comment |
|
| AMP-AMO-CEF-CEP-CFU | MDR |
|
| CEP | |
|
| CEP | |
|
| CEP | |
|
| AMP-AMO-SXT-CEP | |
|
| – | Pan-susceptible |
|
| AMP-CEP | |
|
| AMP-SXT-CEP | |
|
| AMP-SXT-CEP | |
|
| AMP-SXT | |
|
| CEP | |
|
| AMP-AMO-CEP | |
|
| AMP | |
|
| SXT | |
|
| – | Pan-susceptible |
|
| SXT-CEF-CEP-CFU-CFP-AZT-PIP | MDR |
|
| SXT | |
|
| SXT-CEF-CEP-CFU-CFP-AZT-PIP | MDR |
|
| – | Pan-susceptible |
|
| AMP-SXT-COL-CEP-CFU-NTR | MDR |
|
| AMP-NTR | |
|
| AMP-AMO-COL-CEP-CFU-NTR | MDR |
|
| AMP-AMO-COL-CEF-CEP-CFU-NTR | MDR |
|
| AMP-AMO-COL-CEF-CFT-CEP-CFU-NTR-ERT | MDR |
AMP, Ampicillin; AMO; Amoxicillin-Clavulanate; SXT, trimethopprim-sulfamethoxazole; COL, Colistin; IMP, imipenem; CEF, Cefoxitine; CFT, Cefotaxim; CEP, Cephalothin; CFU, Cefuroxime; CFP, Cefepime; AZT, Aztreonam; ERY, Erythromycin; NTR, Nitrofurantoin; PIP, Piperacillin-Tazobactum; ERT, Ertapenem.
In boldface type are isolates found to be multi-drug resistant (MDR).
Figure 2Distinct patterns among staphylococci (panel A), enterococci (panel B) and streptococci (panel C) following RAPD genotyping.
One isolate per lane.
Staphylococcus aureus from cows (n = 1) and humans (n = 4) with similar Spa type, t645.
| Date of collection | Isolate number | Source | Location | DST | Spa repeat | Spa type | ST |
| 23-Feb-2010 | Ky9c | Cow (milk) | Katale (Farm A1) | RRSSSSSSSSSSSS | 14∶44∶13∶12∶17∶23∶18∶17 | t645 | ST-121 |
| 23-Feb-2010 | Ky17n | Human (nares) | Katale (Farm A1) | RRRRSSSSSSSSSS | 14∶44∶13∶12∶17∶23∶18∶17 | t645 | ST-121 |
| 3-Jul-2010 | Ky2n | Human (nares) | Kisubi (Farm A9) | RRRRSSSSSSSSSS | 14∶44∶13∶12∶17∶23∶18∶17 | t645 | ST-121 |
| 10-Dec-2010 | Ky6n | Human (nares) | Entebbe (Farm B1) | RRRRSSSSSSSSSS | 14∶44∶13∶12∶17∶23∶18∶17 | t645 | ST-121 |
| 4-Mar-2011 | 105n | Human (nares) | Wakiso (Farm A12) | RRRRSSSSSSSSSS | 14∶44∶13∶12∶17∶23∶18∶17 | t645 | ST-121 |
Drug susceptibility testing. R, Resistant, S, susceptible, with respect to drugs in the following order: Ampicillin; Penicillin G; Trimethopprim-sulfamethoxazole; Tetracycline; Cefoxitine; Oxacillin; Amoxicillin-Clavulanate; Teicoplanin; Vancomycin; Clindamycin; Erythromycin; Nitrofurantoin; Rifampicin; Ciprofloxacin.
All S. aureus were methicillin susceptible (MSSA).